---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275888"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:08:51.686338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026

## Summary
- Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.
- Cash, equivalents, and short-term investments at $14.1M; expected to fund operations into 2H 2026.
- Phase 2 KOURAGE trial in AKI with respiratory failure enrollment ongoing; data expected 1H 2026.
- Positive FDA discussions on acute pancreatitis pivotal trial; final design expected 1H 2026.
- Collaboration with Telperian to leverage AI analytics for pivotal trial design.

## SEC filing metadata
- accession: 0001193125-25-275888
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/0001193125-25-275888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/ck0001534133-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275888
- JSON: https://secwatch.observer/filing/0001193125-25-275888.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.